![ODAC Slams Spectrum for Massaging Data From Two Bladder Cancer Trials](https://cdn.cancerletter.com/media/2016/09/art-42-34-alchemy.jpg)
![ODAC Slams Spectrum for Massaging Data From Two Bladder Cancer Trials](https://cdn.cancerletter.com/media/2016/09/art-42-34-alchemy.jpg)
Cover Story
A brief consult with an undergraduate earning a B or above in Statistics 101 might have acquainted Spectrum Pharmaceuticals executives with all the science that would have saved them from a devastating encounter with an FDA advisory committee.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Trending Stories
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers
- High school science competitions shaped the careers of Regeneron’s co-founders—now, they’re paying it forward
NCI’s Youth Enjoy Science (YES) program also invests in student scientists - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission